Abstract
335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have